Spots Global Cancer Trial Database for Study of ONO-7579 in Patients With Advanced Solid Tumors/ NTRK Gene Fusion Positive Advanced Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of ONO-7579 in Patients With Advanced Solid Tumors/ NTRK Gene Fusion Positive Advanced Solid Tumors
Official Title: An Open-label, Multi-center, Dose-escalation and Expansion Study to Evaluate the Safety and Efficacy of ONO-7579 in Patients With Advanced Solid Tumors/ NTRK Gene Fusion Positive Advanced Solid Tumors
Study ID: NCT03182257
Conditions
Interventions
Study Description
Brief Summary: This study will determine the safety and maximum tolerated dose of ONO-7579 in patients with advanced solid tumors, and evaluate efficacy of ONO-7579 in patients with advanced solid tumors harboring NTRK gene fusions.
Detailed Description: The trial was designed to be a Phase 1/2 trial, but was terminated without progressing to Phase 2.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Montefiore Medical Center, Lake Success, New York, United States
Mount Sinai, New York, New York, United States
Greenville Hospital System University Medical Center, Greenville, South Carolina, United States
Mary Crowley Cancer Research Center, Dallas, Texas, United States
Beatson West of Scotland Cancer Centre, Glasgow, Scotland, United Kingdom
Contact Details
Name: Drug Development Division
Affiliation: Ono Pharmaceutical Co. Ltd
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
